2023-06 : First Patient Dosed in Phase Ib/II Trial Evaluating Tiprelestat for Treatment of COVID-19

2023-05 : Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

2022-09 : Proteo Biotech AG becomes tiakis Biotech AG.

2022-06 : Move to a new and larger office in Kiel, Germany.

2022-01 : tiakis Biotech AG has partnered with Northway Biotech to scale up its production capabilities.

2021-12 : German Federal Ministry of Education and Research („BMBF“) selects tiakis Biotech AG to develop Tiprelestat as a potential therapeutic for COVID-19.

2021-10 : New anchor investor Elevat3 Capital joins tiakis Biotech AG.